C. Fernández-Metzler

发表

Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.

Youwei Yan, P. Coleman, L. Kuo, 2007, Bioorganic & medicinal chemistry letters.

Collection of selected reaction monitoring and full scan data on a time scale suitable for target compound quantitative analysis by liquid chromatography/tandem mass spectrometry.

R. King, C. Fernández-Metzler, Richard Gundersdorf, 2003, Rapid communications in mass spectrometry : RCM.

Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics

P. Coleman, C. Leu, S. Rodan, 2002 .

Non-peptide αvβ3 antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl β-amino acids as aspartic acid replacements

P. Coleman, C. Leu, S. Rodan, 2002 .

Biomarker Assay Validation by Mass Spectrometry

O. Laterza, B. Desilva, R. Steenwyk, 2022, The AAPS Journal.

Applications of low-flow LC-SRM for the analysis of large molecules in pharmaceutical R&D.

Michael E. Lassman, C. Fernández-Metzler, 2014, Bioanalysis.

Mechanistic investigation of ionization suppression in electrospray ionization

Timothy Olah, Richard King, T. Olah, 2000, Journal of the American Society for Mass Spectrometry.

Method for Continuous Monitoring of Electrospray Ion Formation

R. King, L. Bachmann, C. Fernández-Metzler, 2017, Journal of The American Society for Mass Spectrometry.

The development and cross-validation of methods based on radioimmunoassay and LC/MS-MS for the quantification of the class III antiarrhythmic agent, MK-0499, in human plasma and urine.

T. Olah, J. Ellis, T. Greber, 1995, Journal of pharmaceutical and biomedical analysis.

Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay.

T. Olah, A. S. Yuan, J. Gilbert, 1993, Journal of pharmaceutical and biomedical analysis.

Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.

P. Coleman, C. Leu, J. Huff, 2003, Journal of medicinal chemistry.

Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.

P. Coleman, C. Leu, G. Wesolowski, 2004, Journal of medicinal chemistry.

Nonpeptide αvβ3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent αvβ3 Antagonists for the Prevention and Treatment of Osteoporosis

P. Coleman, C. Leu, G. Wesolowski, 2004 .

Disposition of a novel and potent αvβ3 antagonist in animals, and extrapolation to man

S. Rodan, J. Lin, T. Prueksaritanont, 2004 .

Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP.

John D. Schreier, Youwei Yan, P. Coleman, 2007, Bioorganic & medicinal chemistry letters.

Nonpeptide αvβ3 antagonists : identification of potent, chain-shortened 7-oxo RGD mimetics

C. Leu, S. Rodan, G. Rodan, 2005 .

Non-peptide αvβ3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint

C. Leu, S. Rodan, D. Kimmel, 2003 .

Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.

B. Wall, Suzie Chen, M. McDonnell, 2012, Bioorganic & medicinal chemistry.

Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.

P. Coleman, C. Leu, S. Rodan, 2002, Bioorganic & medicinal chemistry letters.

Determination of chiral sulfoxides in plasma by normal-phase liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.

C. Miller-Stein, C. Fernández-Metzler, 2002, Journal of chromatography. A.

Determination of potato carboxypeptidase inhibitor in African Green Monkey plasma using 96-well SPE and LC-MS/MS.

M. Rose, J. Cook, C. Fernández-Metzler, 2005, Journal of pharmaceutical and biomedical analysis.

The use of Qtrap technology in drug metabolism.

R. King, C. Fernández-Metzler, 2006, Current drug metabolism.

Negative ion tandem mass spectrometry for the detection of glutathione conjugates.

Richard King, T. Baillie, C. Dieckhaus, 2005, Chemical research in toxicology.

Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates.

T. Baillie, R. King, K. Owens, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.

Youwei Yan, P. Coleman, Christopher D. Cox, 2008, Journal of medicinal chemistry.

Nonpeptide αvβ3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative

C. Leu, S. Rodan, D. Kimmel, 2004 .

Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone

C. Leu, S. Rodan, G. Rodan, 2004 .

Non-Peptide αvβ3 antagonists. Part 6: Design and synthesis of αvβ3 antagonists containing a pyridone or pyrazinone central scaffold

C. Leu, S. Rodan, T. Prueksaritanont, 2003 .